(Q43583421)

24 November 2017

title

Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques (English)

1 reference

24 November 2017

1 reference

1 reference

7

1 reference

24 November 2017

11

Alan W Thomas

1 reference

24 November 2017

Jan A M Langermans

1

1 reference

24 November 2017

Annette Schmidt

2

1 reference

24 November 2017

Richard A W Vervenne

3

1 reference

24 November 2017

Ashley J Birkett

4

1 reference

24 November 2017

J Mauricio Calvo-Calle

5

1 reference

24 November 2017

Meike Hensmann

6

1 reference

24 November 2017

Filip Dubovsky

8

1 reference

24 November 2017

Horst Weiler

9

1 reference

24 November 2017

Elizabeth Nardin

10

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

24 November 2017

1 reference

24 November 2017

volume

23

1 reference

24 November 2017

issue

41

1 reference

24 November 2017

page(s)

4935-4943

1 reference

T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Rationale for development of a synthetic vaccine against plasmodium falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Cytotoxic T cells specific for the circumsporozoite protein of plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

The complexity of protective immunity against liver-stage malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

A prime-boost regime that combines Montanide ISA720 and Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Divergent effect of bacillus Calmette-Guérin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

Rationale for the development of an engineered sporozoite malaria vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.036

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.05.036

1 reference

24 November 2017

1 reference